U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07483294) titled 'Cerebellum-based Imaging Neural Markers for Antipsychotic Response' on March 16.
Brief Summary: This study will investigate neural markers in the cerebellar-cortical circuitry that predict treatment response to antipsychotics in first-episode psychosis. A total of 120 patients diagnosed with a first-episode psychotic disorder will be recruited. All subjects receive naturalistic treatment with either risperidone or aripiprazole for 12 weeks, with dosage and titration followed by standard clinical care. A comprehensive clinical and neuroimaging assessments will be performed before and after treatment.
Study Start Date: Nov. 01, 2025...